Gilead Sciences and Tibotec Pharmaceuticals have finalized an agreement to develop a new once-daily antiretroviral pill that combines the protease inhibitor Prezista with Emtriva, the investigational booster cobicistat, and an investigational new form of Viread called GS 7340.

GS 7340 is expected to be safer and more effective than the current version of Viread (tenofovir). Gilead has stated that GS 7340 will enter Phase 2 clinical trials early next year.

“This is the first time we are developing a protease inhibitor-containing single-tablet regimen, and we’re able to do…

Tibotec Pharmaceuticals and Gilead Sciences have agreed to develop a new once-daily combination antiretroviral pill that combines the protease inhibitor Prezista with the investigational booster cobicistat.

In addition, the companies are currently in negotiations to develop a second pill combining Prezista, cobicistat, Emtriva, and an investigational new form of Viread called GS 7340.

“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take,” said Dr. Johan Van Hoof,…

This article is the first in a two-part series discussing Dr. Patrick Yeni’s presentation at the 18th Conference on Retroviruses and Opportunistic Infections, entitled “15 Years of HAART: What Does the Future Hold?” The first article discusses new antiretrovirals and treatments for HIV. The second article discusses ongoing research efforts to find a cure for HIV.

Highly active antiretroviral therapy has improved over the past 15 years and is now more effective, less toxic, and easier to take than earlier treatment regimens. However, there is still room for improvement,…

Este artículo es el primero de una serie de dos en los que se debate sobre la presentación del Dr. Patrick Yeni en la “18ª Conferencia Sobre Retrovirus e Infecciones Oportunistas”, titulada “15 años de la HAART: ¿qué nos depara el futuro?” Este primer artículo analiza los nuevos antirretrovirales y tratamientos para VIH. El segundo artículo habla de los esfuerzos de investigación en curso destinados a encontrar una cura para el VIH.

La terapia antirretroviral altamente activa (HAART, por sus siglas en inglés) ha mejorado en los últimos 15 años…